Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Emadine er større end risiciene ved symptomatisk behandling af sæsonbetinget allergisk konjunktivitis.
The Committee for Medicinal Products for Human Use (CHMP) decided that Emadine’ s benefits are greater than its risks for the symptomatic treatment of seasonal allergic conjunctivitis.